SCHEMBL5730878

SCHEMBL5730878

CC(C)(C)c1cccc([C]2CCC3(CC2)OCCO3)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.41
RXRA P19793 2/20 0.38
RXRB P28702 2/20 0.38
ICMT O60725 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
TMEM97 Q5BJF2 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
CYP26B1 Q9NR63 3/20 0.32
CYP26A1 O43174 2/20 0.32
TACR1 P25103 1/20 0.32
PTAFR P25105 1/20 0.32
CTSS P25774 1/20 0.31
CTSK P43235 1/20 0.31
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31
OPRK1 P41145 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5729388 0.84 KIF11 (0.46) KIF11RXRARXRBHDAC4HDAC2
SCHEMBL5730618 0.81 KIF11 (0.44) KIF11RXRARXRBHDAC4HDAC2
SCHEMBL5729232 0.80 KIF11 (0.45) KIF11RXRARXRBHDAC4HDAC2
SCHEMBL5730229 0.78 KIF11 (0.44) KIF11RXRARXRBHDAC4HDAC2
SCHEMBL5667294 0.76 RXRA (0.38) KIF11RXRARXRBHDAC4HDAC2
SCHEMBL2874345 0.75 KIF11 (0.50) KIF11RXRARXRBHDAC4HDAC2
SCHEMBL10227364 0.73 KIF11 (0.38) KIF11RXRARXRBCTSSCTSK
SCHEMBL12398717 0.73 HTR5A (0.36) KIF11SMN1; SMN2ALDH1A1GAAHPGD
SCHEMBL4260083 0.72 KIF11 (0.51) KIF11RXRARXRBHDAC4HDAC2
SCHEMBL5729463 0.72 KIF11 (0.47) KIF11RXRARXRBHDAC4HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735293-A2 SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2006-12-27 EP disclosed
US-20050239790-A1 Substituted hydroxyethylamine aspartyl protease inhibitors ELAN PHARMACEUTICALS, INC. 2005-10-27 US disclosed
WO-2005087752-A2 SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239790-A1 Substituted hydroxyethylamine aspartyl protease inhibitors DNPEP, MME, ANPEP KIF11 4615/4885RXRA 4803/4885RXRB 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.